A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
Clinical trial NCT04538664 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04538664
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-13
- Primary completion
- 2023-05-03
- Enrollment
- 308
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.